USA flag logo/image

An Official Website of the United States Government

Development of a Novel Cytomegalovirus Drug

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
29152
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
29152
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Triplex Pharmaceutical
9391 Grogans Mill Road The Woodlands, TX 77380
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1995
Title: Development of a Novel Cytomegalovirus Drug
Agency: HHS
Contract: 1 R43 AI38767-01,
Award Amount: $100,000.00
 

Abstract:

Cytomegalovirus (CMV) causes severe infections in infants, organ transplant recipients and AIDS patlong term objective of this work is to treat humans who have cytomegalovirus infections with a novelspecific aims of this grant are to perform animal pharmacology studies, including efficacy, pharmacodisposition, and toxicity studies in mice after intravenous or oral administration of the antiviralseveral drugs that are currently available for the treatment of CMV, these drugs often only delay thinduced pathology, cause serious toxicity, and are subject to the development of resistance. There idevelopment of more effective and novel drugs for the treatment of CMV. T01132 is a non-nucleoside capproximately ten times more potent than ganciclovir in vitro. It is believed to have a novel mechanagainst ganciclovir-resistant CMV, and exhibited low in vitro and in vivo toxicity in pilot experimeproperties, this compound may provide significant advantages over presently available drugs for thecytomegalovirus.

Principal Investigator:

Thomas Wallace
71363

Business Contact:

Small Business Information at Submission:

Triplex Pharmaceutical
9391 Grogans Mill Road The Woodlands, TX 77380

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No